Hydroxocobalamin

Antidote — BLOOD AND BLOOD FORMING ORGANS

Key facts

Hydroxocobalamin is a drug in the Antidote class catalogued in DrugCentral. It was first approved by the FDA in 1978. Recorded indications include Cobalamin deficiency, Pernicious anemia, Prevention of Vitamin B12 Deficiency and Toxic effect of cyanide.

• Drug class: Antidote.
• Indications: Cobalamin deficiency, Pernicious anemia, Prevention of Vitamin B12 Deficiency and Toxic effect of cyanide.
• ATC code: B03BA03 (Vitamin B12 (cyanocobalamin and analogues)).
• Molecular formula: C62H89CoN13O15P; molecular weight 1346.38 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Cobalamin deficiency
• Pernicious anemia
• Prevention of Vitamin B12 Deficiency
• Toxic effect of cyanide

Off-label uses (1)

• Methylmalonic acidemia

Contraindications (1)

• Hypertensive disorder

Mechanism & targets

• Established pharmacologic class: Antidote

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1978-08-16	FDA	—	WATSON LABS

ATC classification

ATC code	Therapeutic hierarchy
B03BA03	BLOOD AND BLOOD FORMING ORGANS › ANTIANEMIC PREPARATIONS › VITAMIN B12 AND FOLIC ACID › Vitamin B12 (cyanocobalamin and analogues)
B03BA53	BLOOD AND BLOOD FORMING ORGANS › ANTIANEMIC PREPARATIONS › VITAMIN B12 AND FOLIC ACID › Vitamin B12 (cyanocobalamin and analogues)
V03AB33	VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Antidotes

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Acute kidney injury	166.1
Hyponatraemia	139.6
Chromaturia	129.5
Lip swelling	93.1
Pneumonia aspiration	80.6
Neutropenic sepsis	77.9
Swelling face	71.9
Hallucination	54.7
Orthostatic hypotension	54.0
Laboratory test interference	48.3
Dizziness	47.0
Somnolence	46.7

Chemical structure

• Molecular formula: C₆₂H₈₉CoN₁₃O₁₅P
• Molecular weight: 1346.38 g/mol
• CAS number: 13422-51-0
• InChIKey: —
• PubChem CID: 44475014

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Hydroxocobalamin used for?

DrugCentral lists the following indications for Hydroxocobalamin: Cobalamin deficiency, Pernicious anemia, Prevention of Vitamin B12 Deficiency and Toxic effect of cyanide.

When was Hydroxocobalamin first approved?

Hydroxocobalamin was first approved by the FDA in 1978.

What drug class does Hydroxocobalamin belong to?

Hydroxocobalamin is in the Antidote class.

What is the chemical formula of Hydroxocobalamin?

Hydroxocobalamin has the molecular formula C62H89CoN13O15P and a molecular weight of 1346.38 g/mol.

Sources

• DrugCentral drug card 4309 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2103737 — compound record and bioactivity
• PubChem CID 44475014 — chemical identifiers
• DrugBank DB00200 — drug record
• FDA UNII Q40X8H422O — substance identity
• DailyMed: FDA labels for Hydroxocobalamin — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.